Oncimmune Holdings PLC Appointment of Joint Broker (1641N)
September 20 2019 - 8:32AM
UK Regulatory
TIDMONC
RNS Number : 1641N
Oncimmune Holdings PLC
20 September 2019
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Appointment of Joint Broker
September 20, 2019 - Oncimmune Holdings plc (AIM: ONC.L), a
leading global immunodiagnostics group, is pleased to announce that
finnCap Limited has been appointed a Joint Broker to the Company,
with immediate effect.
For further information:
Oncimmune Holdings plc
Matthew Hall, Chief Financial Officer
contact@oncimmune.co.uk
Cléa Rosenfeld, Head of Investor Relations
clea.rosenfeld@oncimmune.com
Zeus Capital Limited (Nominated Adviser and Joint Broker)
Andrew Jones, Mike Seabrook
+44 (0)20 3829 5000
finnCap Limited (Joint Broker)
Geoff Nash, Matthew Radley, Tim Redfern
+44 (0)20 7220 0500
Bryan, Garnier & Co Limited (Joint Broker)
Phil Walker, Dominic Wilson
+44 (0)20 7332 2500
Media enquiries:
FTI Consulting
Brett Pollard, Andrew Ward
oncimmune@fticonsulting.com
+44 (0)20 3727 1000
About Oncimmune
Beating cancer, one test at a time
The battle against cancer hinges on early detection and then the
delivery of effective treatment. Oncimmune is working to
revolutionise both the detection of cancer and its treatment by
harnessing the sophisticated disease detecting capabilities of the
immune system to find cancer in its early stages. Our range of
diagnostic tests assist clinicians to identify the presence of
cancer four years or more before standard clinical diagnosis,
whilst our technology platform and sample biobanks are helping
healthcare companies to develop new cancer treatments.
Oncimmune was founded in 2002 and launched its platform
technology in 2009, followed by its first commercial tests,
EarlyCDT Lung and EarlyCDT(R) Liver. To date, over 155,000 tests
have been performed for patients worldwide. EarlyCDT Lung was also
used in what is believed to be the largest randomised controlled
study for the early detection of lung cancer using biomarkers, the
successful National Health Service (NHS) ECLS study of 12,210
high-risk smokers in Scotland which demonstrated EarlyCDT Lung
reduced the incidence of patients with late-stage lung cancer or
unclassified presentation at diagnosis, compared to standard
clinical practice.
Oncimmune, headquartered at its laboratory facility in
Nottingham, UK, has a discovery research centre in Dortmund,
Germany and a CLIA lab in Kansas, US as well as an office in
London, UK and a partner representative office in Shanghai, China.
Oncimmune joined the Alternative Investment Market (AIM) of the
London Stock Exchange in May 2016 under the ticker ONC.L.
What is EarlyCDT Lung?
A blood test using a panel of seven immunogenic proteins for the
testing of tumour-related antibodies specific to lung cancer.
For more information, visit www.oncimmune.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
APPPGUUWBUPBGWU
(END) Dow Jones Newswires
September 20, 2019 09:32 ET (13:32 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2024 to May 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From May 2023 to May 2024